Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Armoring CRAds with p21/Waf-1 shRNAs: the next generation of oncolytic adenoviruses

Cancer Gene Therapy volume 17, pages 585–597 (2010)Cite this article

Subjects

Abstract

Conditionally replicating adenoviruses (CRAds) represent a promising modality for the treatment of neoplastic diseases, including Prostate Cancer. Selectively replicating viruses can be generated by placing a tissue or cancer-specific promoter upstream of one or more of the viral genes required for replication (for example, E1A, E1B). We have previously reported multiple cellular processes that can attenuate viral replication, which in turn compromises viral oncolysis and tumor kill. In this study, we investigated the importance of the cyclin-dependent kinase inhibitor p21/Waf-1, on viral replication and tumor growth. To our knowledge, this is the first report describing the importance of p21/Waf-1shRNA on the induction of an androgen responsive element (ARE) based promoter driving the E1A gene. As a proof of concept, the study emphasizes the use of RNA interference technology to overcome promoter weaknesses for tissue-specific oncolytic viruses, as well as the cellular inhibitor pathways on viral life cycle. Using RNA interference against p21/Waf-1, we were able to show an increase in viral replication and viral oncolysis of prostate cancer cells. Similarly, CRAd viruses that carry p21/Waf-1 shRNA (Ad5-RV004.21) were able to prevent tumor outgrowth that resulted in a marked increase in the mean survival time of tumor-bearing mice compared with CRAd without p21/Waf-1 shRNA (Ad5-RV004). In studies combining Ad5-RV004.21 with Adriamycin, a suprar-additive effect was observed only in CRAds that harbor shRNA against p21/Waf-1. Taken together, these findings of enhanced viral replication in prostate cancer cells by using RNA interference against the cdk inhibitor p21/Waf-1 have significant implications in the development of prostate-specific CRAd therapies.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Imai E, Isaka Y . Strategies of gene transfer to the kidney. Kidney Int 1998; 53: 264–272.

    Article  CAS  PubMed  Google Scholar 

  2. Greber UF, Willetts M, Webster P, Helenius A . Stepwise dismantling of adenovirus 2 during entry into cells. Cell 1993; 75: 477–486.

    Article  CAS  PubMed  Google Scholar 

  3. Pombo A, Ferreira J, Bridge E, Carmo-Fonseca M . Adenovirus replication and transcription sites are spatially separated in the nucleus of infected cells. EMBO J 1994; 13: 5075–5085.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Ben-Israel H, Kleinberger T . Adenovirus and cell cycle control. Front Biosci 2002; 7: d1369–d1395.

    Article  CAS  PubMed  Google Scholar 

  5. Morimoto K, Gosselink J, Kartono A, Hogg JC, Hayashi S, Ogawa E . Adenovirus E1a regulates lung epithelial Icam-1 expression by interacting with transcriptional regulators at its promoter. Am J Physiol Lung Cell Mol Physiol 2009; 296: L361–L371.

    Article  CAS  PubMed  Google Scholar 

  6. Horwitz GA, Zhang K, McBrian MA, Grunstein M, Kurdistani SK, Berk AJ . Adenovirus small e1a alters global patterns of histone modification. Science 2008; 321: 1084–1085.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Ferrari R, Pellegrini M, Horwitz GA, Xie W, Berk AJ, Kurdistani SK . Epigenetic reprogramming by adenovirus e1a. Science 2008; 321: 1086–1088.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Miller DL, Myers CL, Rickards B, Coller HA, Flint SJ . Adenovirus type 5 exerts genome-wide control over cellular programs governing proliferation, quiescence, and survival. Genome Biol 2007; 8: R58.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Jones N, Shenk T . An adenovirus type 5 early gene function regulates expression of other early viral genes. Proc Natl Acad Sci USA 1979; 76: 3665–3669.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Rodriguez R, Schuur ER, Lim HY, Henderson GA, Simons JW, Henderson DR . Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res 1997; 57: 2559–2563.

    CAS  PubMed  Google Scholar 

  11. Dilley J, Reddy S, Ko D, Nguyen N, Rojas G, Working P et al. Oncolytic adenovirus CG7870 in combination with radiation demonstrates synergistic enhancements of antitumor efficacy without loss of specificity. Cancer Gene Ther 2005; 12: 715–722.

    Article  CAS  PubMed  Google Scholar 

  12. Hoti N, Chowdhury W, Hsieh JT, Sachs MD, Lupold SE, Rodriguez R . Valproic acid, a histone deacetylase inhibitor, is an antagonist for oncolytic adenoviral gene therapy. Mol Ther 2006; 14: 768–778.

    Article  PubMed  Google Scholar 

  13. Shiina M, Lacher MD, Christian C, Korn WM . RNA interference-mediated knockdown of p21(WAF1) enhances anti-tumor cell activity of oncolytic adenoviruses. Cancer Gene Ther 2009; 16: 810–819.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Niculescu III AB, Chen X, Smeets M, Hengst L, Prives C, Reed SI . Effects of p21(Cip1/Waf1) at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol Cell Biol 1998; 18: 629–643.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Fuse T, Yamada K, Asai K, Kato T, Nakanishi M . Heat shock-mediated cell cycle arrest is accompanied by induction of p21 CKI. Biochem Biophys Res Commun 1996; 225: 759–763.

    Article  CAS  PubMed  Google Scholar 

  16. Gehen SC, Vitiello PF, Bambara RA, Keng PC, O'Reilly MA . Downregulation of PCNA potentiates p21-mediated growth inhibition in response to hyperoxia. Am J Physiol Lung Cell Mol Physiol 2007; 292: L716–L724.

    Article  CAS  PubMed  Google Scholar 

  17. Suzuki A, Kawano H, Hayashida M, Hayasaki Y, Tsutomi Y, Akahane K . Procaspase 3/p21 complex formation to resist fas-mediated cell death is initiated as a result of the phosphorylation of p21 by protein kinase A. Cell Death Differ 2000; 7: 721–728.

    Article  CAS  PubMed  Google Scholar 

  18. Cayrol C, Knibiehler M, Ducommun B . p21 binding to PCNA causes G1 and G2 cell cycle arrest in p53-deficient cells. Oncogene 1998; 16: 311–320.

    Article  CAS  PubMed  Google Scholar 

  19. van Beusechem VW, Mastenbroek DC, van den Doel PB, Lamfers ML, Grill J, Wurdinger T et al. Conditionally replicative adenovirus expressing a targeting adapter molecule exhibits enhanced oncolytic potency on CAR-deficient tumors. Gene Therapy 2003; 10: 1982–1991.

    Article  CAS  PubMed  Google Scholar 

  20. Nebbioso A, Clarke N, Voltz E, Germain E, Ambrosino C, Bontempo P et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med 2005; 11: 77–84.

    Article  CAS  PubMed  Google Scholar 

  21. Hoti N, Li Y, Chen CL, Chowdhury WH, Johns DC, Xia Q et al. Androgen receptor attenuation of Ad5 replication: implications for the development of conditionally replication competent adenoviruses. Mol Ther 2007; 15: 1495–1503.

    Article  PubMed  Google Scholar 

  22. Yu DC, Chen Y, Seng M, Dilley J, Henderson DR . The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts. Cancer Res 1999; 59: 4200–4203.

    CAS  PubMed  Google Scholar 

  23. Li Y, McCadden J, Ferrer F, Kruszewski M, Carducci M, Simons J et al. Prostate-specific expression of the diphtheria toxin A chain (DT-A): studies of inducibility and specificity of expression of prostate-specific antigen promoter-driven DT-A adenoviral-mediated gene transfer. Cancer Res 2002; 62: 2576–2582.

    CAS  PubMed  Google Scholar 

  24. Lupold SE, Kudrolli TA, Chowdhury WH, Wu P, Rodriguez R . A novel method for generating and screening peptides and libraries displayed on adenovirus fiber. Nucleic Acids Res 2007; 35: e138.

    Article  PubMed  PubMed Central  Google Scholar 

  25. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B . A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 1998; 95: 2509–2514.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Sachs MD, Ramamurthy M, Poel H, Wickham TJ, Lamfers M, Gerritsen W et al. Histone deacetylase inhibitors upregulate expression of the coxsackie adenovirus receptor (CAR) preferentially in bladder cancer cells. Cancer Gene Ther 2004; 11: 477–486.

    Article  CAS  PubMed  Google Scholar 

  27. Huang B, Kochanek S . Adenovirus-mediated silencing of huntingtin expression by shRNA. Hum Gene Ther 2005; 16: 618–626.

    Article  CAS  PubMed  Google Scholar 

  28. Chattopadhyay D, Ghosh MK, Mal A, Harter ML . Inactivation of p21 by E1A leads to the induction of apoptosis in DNA-damaged cells. J Virol 2001; 75: 9844–9856.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Nettelbeck DM, Rivera AA, Balague C, Alemany R, Curiel DT . Novel oncolytic adenoviruses targeted to melanoma: specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter. Cancer Res 2002; 62: 4663–4670.

    CAS  PubMed  Google Scholar 

  30. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996; 274: 373–376.

    Article  CAS  PubMed  Google Scholar 

  31. Leitner S, Sweeney K, Oberg D, Davies D, Miranda E, Lemoine NR et al. Oncolytic adenoviral mutants with E1B19K gene deletions enhance gemcitabine-induced apoptosis in pancreatic carcinoma cells and anti-tumor efficacy in vivo. Clin Cancer Res 2009; 15: 1730–1740.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Satoh M, Wang H, Ishidoya S, Abe H, Moriya T, Hamada H et al. Oncolytic virotherapy for prostate cancer by E1A, E1B mutant adenovirus. Urology 2007; 70: 1243–1248.

    Article  PubMed  Google Scholar 

  33. Raponi M, Arndt GM . Double-stranded RNA-mediated gene silencing in fission yeast. Nucleic Acids Res 2003; 31: 4481–4489.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Graat HC, Witlox MA, Schagen FH, Kaspers GJ, Helder MN, Bras J et al. Different susceptibility of osteosarcoma cell lines and primary cells to treatment with oncolytic adenovirus and doxorubicin or cisplatin. Br J Cancer 2006; 94: 1837–1844.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Mike S, Harrison C, Coles B, Staffurth J, Wilt TJ, Mason MD . Chemotherapy for hormone-refractory prostate cancer. Cochrane Database Syst Rev 2006; 4: CD005247.

    Google Scholar 

  36. DeWeese TL, van der Poel H, Li S, Mikhak B, Drew R, Goemann M et al. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res 2001; 61: 7464–7472.

    CAS  PubMed  Google Scholar 

  37. Small EJ, Carducci MA, Burke JM, Rodriguez R, Fong L, van Ummersen L et al. A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther 2006; 14: 107–117.

    Article  CAS  PubMed  Google Scholar 

  38. Cooper MP, Balajee AS, Bohr VA . The C-terminal domain of p21 inhibits nucleotide excision repair In vitro and In vivo. Mol Biol Cell 1999; 10: 2119–2129.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Wang LG, Ossowski L, Ferrari AC . Overexpressed androgen receptor linked to p21WAF1 silencing may be responsible for androgen independence and resistance to apoptosis of a prostate cancer cell line. Cancer Res 2001; 61: 7544–7551.

    CAS  PubMed  Google Scholar 

  40. Yoo JY, Kim JH, Kim J, Huang JH, Zhang SN, Kang YA et al. Short hairpin RNA-expressing oncolytic adenovirus-mediated inhibition of IL-8: effects on antiangiogenesis and tumor growth inhibition. Gene Therapy 2008; 15: 635–651.

    Article  CAS  PubMed  Google Scholar 

  41. Chu L, Gu J, Sun L, Qian Q, Qian C, Liu X . Oncolytic adenovirus-mediated shRNA against Apollon inhibits tumor cell growth and enhances antitumor effect of 5-fluorouracil. Gene Therapy 2008; 15: 484–494.

    Article  CAS  PubMed  Google Scholar 

  42. Mathews MB, Shenk T . Adenovirus virus-associated RNA and translation control. J Virol 1991; 65: 5657–5662.

    CAS  PubMed  PubMed Central  Google Scholar 

  43. Lu S, Cullen BR . Adenovirus VA1 noncoding RNA can inhibit small interfering RNA and MicroRNA biogenesis. J Virol 2004; 78: 12868–12876.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Koshiji M, Kageyama Y, Pete EA, Horikawa I, Barrett JC, Huang LE . HIF-1alpha induces cell cycle arrest by functionally counteracting Myc. EMBO J 2004; 23: 1949–1956.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Schmaltz C, Hardenbergh PH, Wells A, Fisher DE . Regulation of proliferation-survival decisions during tumor cell hypoxia. Mol Cell Biol 1998; 18: 2845–2854.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Shen BH, Hermiston TW . Effect of hypoxia on Ad5 infection, transgene expression and replication. Gene Therapy 2005; 12: 902–910.

    Article  CAS  PubMed  Google Scholar 

  47. Wang YA, Elson A, Leder P . Loss of p21 increases sensitivity to ionizing radiation and delays the onset of lymphoma in atm-deficient mice. Proc Natl Acad Sci USA 1997; 94: 14590–14595.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Park SH, Park JY, Weiss RH . Antisense attenuation of p21 sensitizes kidney cancer to apoptosis in response to conventional DNA damaging chemotherapy associated with enhancement of phospho-p53. J Urol 2008; 180: 352–360.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This study was supported in part by grants from; FAMRI- the Flight Attendant Medical Research Institute YCSA award to Naseruddin Höti and The National Institutes of Health 1R01CA121153-01A2 to Dr Ronald Rodriguez.

Author information

Authors and Affiliations

  1. Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    N Höti, W H Chowdhury, S Mustafa, J Ribas, M Castanares, T Johnson, M Liu, S E Lupold & R Rodriguez

Authors
  1. N Höti
    View author publications

    Search author on:PubMed Google Scholar

  2. W H Chowdhury
    View author publications

    Search author on:PubMed Google Scholar

  3. S Mustafa
    View author publications

    Search author on:PubMed Google Scholar

  4. J Ribas
    View author publications

    Search author on:PubMed Google Scholar

  5. M Castanares
    View author publications

    Search author on:PubMed Google Scholar

  6. T Johnson
    View author publications

    Search author on:PubMed Google Scholar

  7. M Liu
    View author publications

    Search author on:PubMed Google Scholar

  8. S E Lupold
    View author publications

    Search author on:PubMed Google Scholar

  9. R Rodriguez
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to R Rodriguez.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies the paper on Cancer Gene Therapy website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Höti, N., Chowdhury, W., Mustafa, S. et al. Armoring CRAds with p21/Waf-1 shRNAs: the next generation of oncolytic adenoviruses. Cancer Gene Ther 17, 585–597 (2010). https://doi.org/10.1038/cgt.2010.15

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/cgt.2010.15

Keywords

This article is cited by

Search

Advanced search

Quick links